The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 07, 2023
Filed:
Dec. 10, 2019
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Universite Paris—sud, Orsay, FR;
Centre Hospitalier Regional Universitaire DE Lille, Lille, FR;
Université DE Droit ET DE LA Santé DE Lille 2, Lille, FR;
Petrus Lenting, Le Kremlin-Bicetre, FR;
Cécile Denis, Le Kremlin-Bicetre, FR;
Olivier Christophe, Le Kremlin-Bicetre, FR;
Paulette Legendre, Le Kremlin-Bicetre, FR;
Antoine Rauch, Lille, FR;
Sophie Susen, Lille, FR;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDECALE), Paris, FR;
UNIVERSITE PARIS—SUD, Orsay, FR;
CENTRE HOSPITALIER REGIONALE UNIVERSITAIRE DE LILLE, Lille, FR;
UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2, Lille, FR;
Abstract
The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).